Desmoid Tumor Pipeline Analysis Highlights New Therapies and Trials
A new report details advancements in desmoid tumor treatments, covering clinical trials and emerging therapies from over four companies involved in the drug development landscape.
A comprehensive report has been released analyzing the pipeline of desmoid tumor treatments, offering insights into ongoing clinical trials and emerging therapies from more than four companies.
The analysis highlights key developments, including a Phase 2 study initiated by SpringWorks Therapeutics Inc. on September 15, 2026, to assess nirogacestat's efficacy and safety in Japanese adults. Desmoid tumors, also known as aggressive fibromatosis, are rare, locally invasive soft tissue growths that, while not metastatic, can lead to significant patient morbidity.
Key companies actively developing treatments for desmoid tumors include Immunome and Iterion Therapeutics. The report identifies promising pipeline therapies such as AL102, nirogacestat, cryoablation, sirolimus, imatinib, and FOG-001. It provides detailed profiles of these drugs, categorized by development stage, route of administration, and molecule type.
Furthermore, the report examines inactive or discontinued projects within the desmoid tumor space. It also delves into licensing agreements, collaborations, and financing details that are shaping the future market for these treatments. Immunome's AL102, an investigational small molecule gamma-secretase inhibitor, is currently in Phase 3 clinical trials.
The analysis offers a thorough overview of both active and future treatment options, providing a snapshot of the current landscape for desmoid tumor therapeutics.